Optimization of Functional State of the Liver in Patients with Chd on the Background of Rosuvastatin Intake
No Thumbnail Available
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Univer Publishing
Abstract
Description
In 2019, 18.6 million people died of cardiovascular diseases (CVDs) worldwide. Coronary heart disease (CHD) is the leading cause of death from CVDs. One of the main risk factors for atherosclerosis and its complications is hyperlipidemia. The progress achieved is due in no small part to the emergence of a new class of hypolipidemic drugs belonging to the group of statins - HMG-CoA reductase inhibitors. Statins are the most effective means of combating atherosclerosis, having proven the ability to slow or completely stop its progression. Usually, statin therapy is well tolerated, but side effects can develop, including elevation of hepatic enzymes - aminotransferases. In this regard, the administration of statins together with hepatoprotective drugs, such as milk thistle extract leads to a decrease in the side effects of hypolipidemic therapy in patients with CHD.
Keywords
CHD, statins, milk thistle extract, liver, liver transaminases